CORC

在结果中检索

CORC

浏览/检索结果: 共27条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model 期刊论文
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10
作者:  Zou, Hui-xi;  Zhang, Yu-feng;  Zhong, Da-fang;  Jiang, Yong;  Liu, Fei
收藏  |  浏览/下载：19/0  |  提交时间：2022/01/04
Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans 期刊论文
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10
作者:  Meng, Jian;  Zhang, Hua;  Bao, Jing-jing;  Chen, Zhen-dong;  Liu, Xiao-yun
收藏  |  浏览/下载：69/0  |  提交时间：2021/06/11
Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans 期刊论文
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10
作者:  Meng, Jian;  Zhang, Hua;  Bao, Jing-jing;  Chen, Zhen-dong;  Liu, Xiao-yun
收藏  |  浏览/下载：71/0  |  提交时间：2021/06/11
Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers 期刊论文
INVESTIGATIONAL NEW DRUGS, 2021, 页码: 8
作者:  Zhu, Yun-ting;  Zhang, Yi-fan;  Jiang, Jin-fang;  Yang, Yong;  Guo, Li-xia
收藏  |  浏览/下载：27/0  |  提交时间：2021/05/24
Safety, Clinical Activity, and Pharmacokinetics of Al flutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation 期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2020, 卷号: 15, 期号: 6, 页码: 1015-1026
作者:  Shi, Yuankai;  Zhang, Shucai;  Hu, Xingsheng;  Feng, Jifeng;  Ma, Zhiyong
收藏  |  浏览/下载：38/0  |  提交时间：2020/12/24
Synthesis and Biological Evaluation of Oxopyrido[2,3-d] Pyrimidine-7-ones Derivatives as Covalent L85812/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors 期刊论文
LETTERS IN DRUG DESIGN & DISCOVERY, 2019, 卷号: 16, 期号: 8, 页码: 826-834
作者:  Niu, Ao;  Wang, Yang;  Yang, Yushe;  Wei, Jianhai;  Ding, Jian
收藏  |  浏览/下载：12/0  |  提交时间：2020/07/01
Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacology 期刊论文
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2018, 卷号: 18, 页码: 17
作者:  Bing, Zhitong;  Cheng, Zhiyuan;  Shi, Danfeng;  Liu, Xinkui;  Tian, Jinhui
收藏  |  浏览/下载：91/0  |  提交时间：2019/10/09
Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacology 期刊论文
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2018, 卷号: 18
作者:  Bing, Zhitong;  Cheng, Zhiyuan;  Shi, Danfeng;  Liu, Xinkui;  Tian, Jinhui
收藏  |  浏览/下载：74/0  |  提交时间：2019/03/27
Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl) phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor 期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 131, 页码: 107-125
作者:  Liang, Qianmao;  Chen, Yongfei;  Yu, Kailin;  Chen, Cheng;  Zhang, Shouxiang
收藏  |  浏览/下载：37/0  |  提交时间：2018/07/26
Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962
作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E
收藏  |  浏览/下载：34/0  |  提交时间：2018/07/26

©版权所有 ©2017 CSpace - Powered by CSpace